Your AI-Trained Oncology Knowledge Connection!
Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.
Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.
David Nanus, MD, medical oncologist, Weill Cornell Medicine, discusses the impact of atezolizumab for patients with advanced urothelial bladder cancer.
Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.
Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses how the field of hormone receptor (HR)-positive breast cancer has evolved.
Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.
Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.
Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.
Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).
Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.
Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas.
Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.
Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the role that immunotherapy currently plays, and will continue to play, in the treatment landscape of hepatocellular carcinoma (HCC).
Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.
David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).
Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.
Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses the evolving role of surgery in the treatment of patients with metastatic breast cancer.
Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the International Myeloma Working Group’s recently released updated consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma.
Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.
Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).
Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.
Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.
Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.
Laurence Albiges, MD, medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).
Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.
